<DOC>
	<DOCNO>NCT01416623</DOCNO>
	<brief_summary>Henatinib novel oral multitargeted tyrosine kinase inhibitor antitumor antiangiogenic activity . This study design evaluate safety tolerability Henatinib patient Advanced Solid Malignancies</brief_summary>
	<brief_title>A Phase I Study Henatinib Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description>1 . To evaluate safety tolerability Henatinib , maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) . 2 . To determine pharmacokinetic profile Henatinib metabolites . 3 . To assess preliminary antitumor activity . 4 . To determine preliminary regimen phase II study .</detailed_description>
	<criteria>1 . Histologically cytologic ( except sputum smear ) confirm metastatic locally advanced solid tumor ( At least one measurable lesion long diameter ≥20 mm use conventional technique large 10 mm diameter spiral CT scan ) . 2 . Life expectancy 12 week . 3 . Lack standard treatment standard treatment failure . 4 . Screening laboratory value within follow parameter : 1 . HB : ≥90g/L 2 . ANC : ≥1.5×109/L 3 . PLT : ≥100×109/L 5 . ALT AST : ≤1.5×ULN ( But liver metastasis , ALT AST : ≤5×ULN ) 1 . Serum total bilirubin : ≤1.5×ULN 2 . Serum creatinine : ≤1.5×ULN 3 . Creatinie clearance rate : ≥60ml/min 4 . Electrolytes normal return normal treatment 6 . Recovery clinically significant AEs relate prior therapy . Duration late therapy 6 week nitroso mitomycin , 4 week radiotherapy , chemotherapy , immunotherapy anticancer treatment ( test drug , biologics , hormone surgery ) . 7 . Signed date informed consent . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Evidence CNS metastasis . 2 . Major surgery , open biopsy , obvious trauma within 4 week treatment . 3 . Obvious peritoneal implantation pelvic obstruction . 4 . II level , peripheral neuropathy ( NCI CTC AE v3.0 ) . 5 . Known history neurological psychiatric disease . 6 . Suffering high blood pressure reduce follow range monotherapy ( systolic blood pressure &lt; 140 mmHg , diastolic blood pressure &lt; 90 mmHg ) . 7 . History heart disease : &gt; NYHA II class congestive heart failure ; unstable coronary artery disease ( patient last myocardial infarction 12 month enrol ) , arrhythmias require antiarrhythmic drug therapy . Bazett 's correct QTc ≥ 480 m measure . ( Note : If ECG QTc interval ≥ 480 m screening period , must repeat 2 time , separate least 24 hour , average QTc 3 time must &lt; 480 , patient enrol study ) . 8 . Coagulopathy ( PT &gt; 16 , APTT &gt; 43 , TT &gt; 21 , Fbg &lt; 2 g / L ) , bleed tendency receive therapy thrombolysis anticoagulation . 9 . Confirmed active gastrointestinal ulcer . 10 . Active severe infection ( &gt; NCICTC 3.0 standard 2 ) . 11 . Patients severe epilepsy require drug treatment ( steroids antiepileptic drug ) . 12 . Other serious illness condition . 13 . Treated VEGFR TKIs sunitinib solafenib study entry . 14 . Less 4 week last clinical trial . 15 . Pregnancy , breastfeed woman woman childbearing age without effective contraception . 16 . Allergic known history hypersensitivity henatinib component . 17 . Drug abuse , drug mental illness may affect patient participation study assessment research result . 18 . Any unstable likely situation harm safety compliance patient study . 19 . Any factor influence usage oral administration . 20 . Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Advanced solid cancer</keyword>
	<keyword>Henatinib</keyword>
	<keyword>phase I</keyword>
</DOC>